Last reviewed · How we verify
NCT03390322
Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients
NA trial testing DiaGone™ in Diabetes Mellitus, Type 2 in 31 participants. Completed in 31 August 2024.
31 August 2024
Quick facts
| Lead sponsor | Digma Medical Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 28 July 2017 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 3 locations across Israel, Czechia |
Drugs / interventions tested
- DiaGone™
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Digma Medical Ltd.
Who can join
Adults 18 to 75, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, prospective, open label study of the Duodenal Glycemic Control™ procedure on type 2 diabetes patients sub-optimally controlled, to examine the safety and initial performance of the DiaGone™ system.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bariatric and Metabolic Endoscopy: A New Paradigm.
Telese A, Sehgal V, Magee CG, Naik S, et al · · 2021 · cited 9× · PMID 34142665 · DOI 10.14309/ctg.0000000000000364 -
Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity.
Ghusn W, Calderon G, Abu Dayyeh BK, Acosta A. · · 2024 · cited 4× · PMID 39206501 · DOI 10.5946/ce.2024.005 -
Duodenal Laser Ablation for Treatment of Type 2 Diabetes: Results of First in Human Study.
Kovarova V, Lankova I, Machytka E, Knotkova K, et al · · 2025 · cited 2× · PMID 39976927 · DOI 10.1002/ueg2.12762
Verify or expand the search:
- PubMed search for NCT03390322
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Digma Medical Ltd. trials
Trials by the same sponsor.
- NCT07331857 — Digma System First in Human (FIH) Study · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03390322 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Digma Medical Ltd.
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03390322.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing